Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Cardiovascular Imaging Reports
Published in: Current Cardiovascular Imaging Reports 4/2019

Open Access 01-04-2019 | Magnetic Resonance Imaging | Molecular Imaging (J Wu and P Nguyen, Section Editors)

Molecular Imaging to Monitor Left Ventricular Remodeling in Heart Failure

Published in: Current Cardiovascular Imaging Reports | Issue 4/2019

Login to get access

Abstract

Purpose of Review

Cardiovascular diseases are the leading cause of deaths worldwide. Many complex cellular and molecular pathways lead to myocardial remodeling after ischemic insults. Anatomy, function, and viability of the myocardium can be assessed by modern medical imaging techniques by both visualizing and quantifying damages. Novel imaging techniques aim for a precise and accurate visualization of the myocardium and for the detection of alternations at the molecular level.

Recent Findings

Magnetic resonance imaging assesses anatomy, function, and tissue characterization of the myocardium non-invasively with high spatial resolution, sensitivity, and specificity. Using hyperpolarized magnetic resonance imaging, molecular and metabolic conditions can be assessed non-invasively. Single photon-emission tomography and positron-emission tomography are the most sensitive techniques to detect biological processes in the myocardium. Cardiac perfusion, metabolism, and viability are the most common clinical targets. In addition, molecular-targeted imaging of biological processes involved in heart failure, such as myocardial innervation, inflammation, and extracellular matrix remodeling, is feasible.

Summary

Novel imaging techniques can provide a precise and accurate visualization of the myocardium and for the detection of alternations at molecular level.
Literature
1.
2.
3.
4.
van Slochteren FJ. Advanced measurement techniques of regional myocardial function to assess the effects of cardiac regenerative therapy in different models of ischemic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012;13:808–18.PubMedCrossRef
5.
6.
Mavrogeni S. T1 and T2 mapping in cardiology: “mapping the obscure object of desire”. Cardiology. 2017;138:207–17.PubMedCrossRef
7.
•• Yla-Herttuala E. Quantification of myocardial infarct area based on TRAFFn relaxation time maps – comparison with cardiovascular magnetic resonance late gadolinium enhancement, T1ρ and T2 in vivo. J Cardiovasc Magn Reson. 2018;20:34. This study provides the first myocardial infarction study in vivo done with T RAFFn relaxation time maps and those results are compared to other MRI imaging methods. PubMedPubMedCentralCrossRef
8.
9.
Blankesteijn WM. Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiol Scand. 2001;173:75–82.PubMedCrossRef
10.
11.
Baxa J. T1 mapping of the ischemic myocardium: review of potential clinical use. Eur J Radiol. 2016;85:1322–928.CrossRef
12.
13.
Palazzuoli A. The impact if infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study. Int J Cardiovasc Imaging. 2015;5:1037–44.CrossRef
14.
van den Borne SW. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010;7:30–7.PubMedCrossRef
15.
Saeed M. Magnetic resonance imaging for characterizing myocardial diseases. Int J Cardiovasc Imaging. 2017;33:1395–414.PubMedCrossRef
16.
17.
Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661.PubMed
18.
• Apps A. Hyperpolarized magnetic resonance for in vivo real-time metabolic imaging. Heart. 2018;104:1484–91. This review article provides great overview about use of hyperpolarized MRI in vivo. PubMedPubMedCentralCrossRef
19.
Ghosn MG. Important advances in technology and unique applications related to cardiac magnetic resonance imaging. Methodist Debakey Cardiovasc J. 2014;10:159–62.PubMedPubMedCentralCrossRef
20.
21.
22.
Wong DT. The role of cardiac magnetic resonance imaging following acute myocardial infarction. Eur Radiol. 2012;22:1757–68.PubMedCrossRef
23.
Reuben MT. Distal coronary embolization following acute myocardial infarction increases early infarct size and late left ventricular wall thinning in a porcine model. J Cardiovasc Magn Reson. 2015;17:106.CrossRef
24.
Watanabe E. Infarct tissue heterogeneity by contrast-enhanced magnetic resonance imaging is a novel predictor of mortality in patients with chronic coronary artery disease and left ventricular dysfunction. Circ Cardiovasc Imaging. 2014;7:887–94.PubMedPubMedCentralCrossRef
25.
26.
27.
28.
Larroza A. Texture analysis of cardiac cine magnetic resonance imaging to detect nonviable segments in patients with chronic myocardial infarction. Med Phys. 2018;4:1471–80.CrossRef
29.
Payne AR, Berry C, Kellman P, Anderson R, Hsu LY, Chen MY, et al. Bright-blood T(2)-weighted MRI has high diagnostic accuracy for myocardial hemorrhage in myocardial infarction: a preclinical validation study in swine. Circ Cardiovasc Imaging. 2011;4:738–45.PubMedPubMedCentralCrossRef
30.
31.
Caudron J. Evaluation of left ventricular diastolic function with cardiac MR imaging. Radiographics. 2011;31:239–59.PubMedCrossRef
32.
Shehata ML. Myocardial tissue tagging with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2009;11:11–55.CrossRef
33.
Khan JN. Comparison of cardiovascular magnetic resonance feature tracking and tagging for the assessment of left ventricular systolic strain in acute myocardial infarction. Eur J Radiol. 2015;84:840–8.PubMedCrossRef
34.
Fahmy AS. Grey blood late gadolinium enhancement cardiovascular magnetic resonance for improved detection of myocardial scar. J Cardiovasc Magn Reson. 2018;20:20.CrossRef
35.
Maestrini V. T1 mapping for characterization of intracellular and extracellular myocardial diseases in heart failure. Curr Cardiovasc Imaging Rep. 2014;7:9287.PubMedPubMedCentralCrossRef
36.
37.
Kis E. Cardiac magnetic resonance imaging of the myocardium in chronic kidney disease. Kidney Blood Press Res. 2018;43:134–42.PubMedCrossRef
38.
Klein C. The influence of myocardial blood flow and volume of distribution on late gd-dtpa kinetics in ischemic heart failure. J Magn Reson Imaging. 2004;20:588–93.PubMedCrossRef
39.
40.
Messroghli DR. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European association for cardiovascular imaging (EACVI). J Cardiovasc Magn Reson. 2017;19:75.PubMedPubMedCentralCrossRef
41.
42.
Mark Haacke E, et al. Magnetic resonance imaging, physical principles and sequence design. 1st ed. Hoboken: A John Wiley And Sons, Inc.; 1999.
43.
44.
Sanz J. Myocardial mapping with cardiac magnetic resonance: the diagnostic value of novel sequences. Rev Esp Cardiol (Eng Ed). 2016;69:849–61.CrossRef
45.
Aletras AH. Retrospective determination of the area at risk for reperfused acute myocardial infarction with t2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (dense) functional validations. Circulation. 2006;113:1865–70.PubMedCrossRef
46.
47.
Graham-Brown MP. Novel cardiac nuclear magnetic resonance method for noninvasive assessment of myocardial fibrosis in hemodialysis patients. Kidney Int. 2016;90:835–44.PubMedCrossRef
48.
49.
50.
Kali A. Determination of location, size, and transmurality of chronic myocardial infarction without exogenous contrast media by using cardiac magnetic resonance imaging at 3 T. Circ Cardiovasc Imaging. 2014;7:471–81.PubMedPubMedCentralCrossRef
51.
Stoffers RH. Assessment of myocardial injury after reperfused infarction by T1r cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2017;19:17.PubMedPubMedCentralCrossRef
52.
Jackowski C. Postmortem unenhanced magnetic resonance imaging of myocardial infarction in correlation to histological infarction age characterization. Eur Heart J. 2006;27:2459–67.PubMedCrossRef
53.
54.
Mustafa HS. Longitudinal rotating frame relaxation time measurements in infarcted mouse myocardium in vivo. Magn Reson Med. 2013;69:1389–95.CrossRef
55.
56.
57.
•• Liimatainen T. MRI contrasts in high rank rotating frames. Magn Reson Med. 2015;73:254–62. This study provides the theoretical background behind the T RAFFn relaxation time method. PubMedCrossRef
58.
Kettunen MI. Low spin-lock field T1 relaxation in the rotating frame as a sensitive MR imaging marker for gene therapy treatment response in rat glioma. Radiology. 2007;243:796–803.PubMedCrossRef
59.
60.
61.
Golman K. Cardiac metabolism measured noninvasively by hyperpolarized 13C MRI. Magn Reson Med. 2008;59:1005–13.PubMedCrossRef
62.
Lau AZ. Reproducibility study for free-breathing measurements of pyruvate metabolism using hyperpolarized (13) C in the heart. Magn Reson Med. 2013;69:1063–71.PubMedCrossRef
63.
Merritt ME. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc Natl Acad Sci U S A. 2007;104:19773–7.PubMedPubMedCentralCrossRef
64.
Aquaro GD. Cardiac metabolism in a pig model of ischemia– reperfusion by cardiac magnetic resonance with hyperpolarized 13C-Pyruvate. IJC Metab Endocr. 2015;6:17–23.CrossRef
65.
Ball DR. Metabolic imaging of acute and chronic infarction in the perfused rat heart using hyperpolarised [1-13C]pyruvate. NMR Biomed. 2013;26:1441–50.PubMedCrossRef
66.
Oh-Ici D. Hyperpolarized metabolic MR imaging of acute myocardial changes and recovery after ischemia-reperfusion in a small-animal model. Radiology. 2016;278:742–51.PubMedCrossRef
67.
Schroeder MA. Measuring intracellular pH in the heart using hyperpolarized carbon dioxide and bicarbonate: a 13C and 31P magnetic resonance spectroscopy study. Cardiovasc Res. 2010;86:82–91.PubMedCrossRef
68.
Lau AZ. Mapping of intracellular pH in the in vivo rodent heart using hyperpolarized [1-13C]pyruvate. Magn Reson Med. 2017;77:1810–7.PubMedCrossRef
69.
Rubler S. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595–602.PubMedCrossRef
70.
71.
Do HP. Non-contrast assessment of microvascular integrity using arterial spin labeled cardiovascular magnetic resonance in a porcine model of acute myocardial infarction. J Cardiovasc Magn Reson. 2018;20:45.PubMedPubMedCentralCrossRef
72.
Ma H. Contrast-enhanced whole-heart coronary MRA at 3.0T for the evaluation of cardiac venous anatomy. Int J Cardiovasc Imaging. 2011;27:1003–9.PubMedCrossRef
73.
Nquyen C. In vivo contrast free chronic myocardial infarction characterization using diffusion-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;16:68.CrossRef
74.
Sosnovik DE. Diffusion spectrum MRI tractography reveals the presence of a complex network of residual myofibers in infarcted myocardium. Circ Cardiovasc Imaging. 2009;2:206–12.PubMedPubMedCentralCrossRef
75.
Payne AR. Bright-blood T2-weighted MRI has higher diagnostic accuracy than dark-blood short tau inversion recovery MRI for detection of acute myocardial infarction and for assessment of the ischemic area at risk and myocardial salvage. Circ Cardiovasc Imaging. 2011;4:210–9.PubMedCrossRef
76.
Arunachalam SP. Regional assessment of in vivo myocardial stiffness using 3D magnetic resonance elastography in a porcine model of myocardial infarction. Magn Reson Med. 2018;79:361–9.PubMedCrossRef
77.
Metha NK. Utility of cardiac magnetic resonance for evaluation of mitral regurgitation prior to mitral valve surgery. J Thorac Dis. 2017;4:S246–56.
78.
Quarto C. Late gadolinium enhancement as a potential marker of increased perioperative risk in aortic valve replacement. Interact Cardiovasc Thorac Surg. 2012;15:45–50.PubMedPubMedCentralCrossRef
79.
80.
81.
Jaarsma C. Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2012;59:1719–28.PubMedCrossRef
82.
Saraste A. PET: is myocardial flow quantification a clinical reality? J Nucl Cardiol. 2012;19:1044–59.PubMedCrossRef
83.
Gupta A. Integrated noninvasive physiological assessment of coronary circulatory function and impact on cardiovascular mortality in patients with stable coronary artery disease. Circulation. 2017;136:2325–36.PubMedPubMedCentralCrossRef
84.
Neglia D. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation. 2002;105:186–93.PubMedCrossRef
85.
Majmudar MD. Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. Eur Heart J Cardiovasc Imaging. 2015;16:900–9.PubMedPubMedCentralCrossRef
86.
Schinkel AF. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32:375–410.PubMedCrossRef
87.
Kiugel M. Dimeric [(68)Ga]DOTA-RGD peptide targeting αvβ 3 integrin reveals extracellular matrix alterations after myocardial infarction. Mol Imaging Biol. 2014;16:793–801.PubMedCrossRef
88.
Allman KC. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151–8.PubMedCrossRef
89.
Beanlands RS. F-18-Fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002–12.PubMedCrossRef
90.
91.
Mielniczuk LM. Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit? Imaging-guided selection of patients with ischemic heart failure for high-risk revascularization improves identification of those with the highest clinical benefit. Circ Cardiovasc Imaging. 2012;5:262–70.PubMedCrossRef
92.
Ling LF. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging. 2013;6:363–72.PubMedCrossRef
93.
Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2129–200.PubMedCrossRef
94.
Knaapen P. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation. 2007;115:918–27.PubMedCrossRef
95.
Tuunanen H, Knuuti J. Metabolic remodelling in human heart failure. Cardiovasc Res. 2011;90:251–7.PubMedCrossRef
96.
Juneau D. The role of nuclear cardiac imaging in risk stratification of sudden cardiac death. J Nucl Cardiol. 2016;23:1380–98.PubMedCrossRef
97.
Travin MI. Current clinical applications and next steps for cardiac innervation imaging. Curr Cardiol Rep. 2017;19:1.PubMedCrossRef
98.
Jacobson AF. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–21.PubMedCrossRef
99.
Narula J. 123I-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: the ADMIRE-HFX study. J Nucl Med. 2015;56:1011–8.PubMedCrossRef
100.
Fallavollita JA. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63:141–9.PubMedCrossRef
101.
Yu M, Bozek J. Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging. 2011;4:435–43.PubMedCrossRef
102.
Sinusas AJ. Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation. J Nucl Med. 2014;55:1445–51.PubMedCrossRef
103.
Saraste A. PET imaging in heart failure: the role of new tracers. Heart Fail Rev. 2017;22:501–11.PubMedCrossRef
104.
105.
Sun M, Opavsky MA. Temporal response and localization of integrins beta1 and beta3 in the heart after myocardial infarction: regulation by cytokines. Circulation. 2003;107:1046–52.PubMedCrossRef
106.
Van den Borne SWM. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol. 2008;52:2017–28.PubMedCrossRef
107.
Higuchi T. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res. 2008;78:395–403.PubMedCrossRef
108.
Sherif HM. Molecular imaging of early αvβ3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats. J Nucl Med. 2012;53:318–23.PubMedCrossRef
109.
Gao H. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2. Eur J Nucl Med Mol Imaging. 2012;39:683–92.PubMedPubMedCentralCrossRef
110.
Knetsch PA. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression. Eur J Nucl Med Mol Imaging. 2011;38:1303–12.PubMedCrossRef
111.
112.
Menichetti L. MicroPET/CT imaging of αvβ3 integrin via a novel 68Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. Eur J Nucl Med Mol Imaging. 2013;40:1265–74.PubMedCrossRef
113.
Grönman M. Imaging of αvβ3 integrin expression in experimental myocardial ischemia with [68Ga]NODAGA-RGD positron emission tomography. J Transl Med. 2017;15:144.PubMedPubMedCentralCrossRef
114.
Jenkins WS. Cardiac αVβ3 integrin expression following acute myocardial infarction in humans. Heart. 2017;103:607–15.PubMedCrossRef
115.
116.
Verjans J. Early molecular imaging of interstitial changes in patients after myocardial infarction: comparison with delayed contrast-enhanced magnetic resonance imaging. J Nucl Cardiol. 2010;17:1065–72.PubMedPubMedCentralCrossRef
117.
Hartikainen J. Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. Eur Heart J. 2017;38:2547–55.PubMedPubMedCentralCrossRef
118.
Rischpler C. Prospective evaluation of 18F-fluorodeoxyglucose uptake in postischemic myocardium by simultaneous positron emission tomography/magnetic resonance imaging as a prognostic marker of functional outcome. Circ Cardiovasc Imaging. 2016;9:e004316.PubMedPubMedCentralCrossRef
119.
120.
Thackeray JT. Molecular imaging of the chemokine receptor CXCR4 after acute myocardial infarction. JACC Cardiovasc Imaging. 2015;8:1417–26.PubMedCrossRef
121.
Lapa C. [(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression after myocardial infarction. JACC Cardiovasc Imaging. 2015;8:1466–8.PubMedCrossRef
122.
Rischpler C. Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI. J Nucl Cardiol. 2016;23:131–3.PubMedCrossRef
123.
124.
125.
Sahul ZH. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging. 2011;4:381–91.PubMedPubMedCentralCrossRef
126.
Su H. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation. 2005;112:3157–67.PubMedCrossRef
127.
Kiugel M. Evaluation of 68Ga-labeled peptide tracer for detection of gelatinase expression after myocardial infarction in rat. J Nucl Cardiol. 2018;25:1114–23.PubMedCrossRef
128.
Fukushima K. Molecular hybrid positron emission tomography/computed tomography imaging of cardiac angiotensin II type 1 receptors. J Am Coll Cardiol. 2012;60:2527–34.PubMedPubMedCentralCrossRef
129.
Metadata
Title
Molecular Imaging to Monitor Left Ventricular Remodeling in Heart Failure
Publication date
01-04-2019
Published in
Current Cardiovascular Imaging Reports / Issue 4/2019
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-019-9487-3

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits